doi:10.3969/j.issn.1004-583X.2025.05.017

Abstract

CLC Number:

R734.2

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.05.017

http://www.lchc.cn/EN/Y2025/V40/I5/473

References 41

[1]	王培宇, 黄祺, 王少东, 等. 《全球癌症统计数据2022》要点解读[J]. 中国胸心血管外科临床杂志, 2024, 31(7):933-954.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231.
[3]	Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: A population-based cohort study[J]. Blood, 2021, 137(14):1959-1969. doi: 10.1182/blood.2020007338 pmid: 33171494
[4]	Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(10):1181-1201.
[5]	Xu Y, Wu T, Ren X, et al. Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: A systematic review and meta-analysis[J]. Front Oncol, 2024, 14:1405147.
[6]	Weitz JI, Haas S, Ageno W, et al. Cancer associated thrombosis in everyday practice: Perspectives from GARFIELD-VTE[J]. J Thromb Thrombolysis, 2020, 50(2):267-277.
[7]	Lyman GH, Culakova E, Poniewierski MS, et al. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer[J]. Thromb Res, 2018, 164 Suppl 1:S112-S118.
[8]	Howlett J, Benzenine E, Cottenet J, et al. Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study[J]. BMC Cancer, 2020, 20(1):461. doi: 10.1186/s12885-020-06930-1 pmid: 32448219
[9]	Khorana AA, Kuderer NM, McCrae K, et al. Healthcare costs of patients with cancer stratified by Khorana score risk levels[J]. J Med Econ, 2021, 24(1):866-873.
[10]	Takemoto T, Soh J, Ohara S, et al. The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery[J]. Surg Today, 2021, 51(9):1480-1487. doi: 10.1007/s00595-021-02243-3 pmid: 33611651
[11]	Pastori D, Cormaci VM, Marucci S, et al. A comprehensive review of risk factors for venous thromboembolism: From epidemiology to pathophysiology[J]. Int J Mol Sci, 2023, 24(4):3169.
[12]	Yan AR, Samarawickrema I, Naunton M, et al. Risk factors and prediction models for venous thromboembolism in ambulatory patients with lung cancer[J]. Healthcare (Basel), 2021, 9(6):778.
[13]	Pabinger I, Ay C, Dunkler D, et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the vienna cancer and thrombosis study (CATS)[J]. J Thromb Haemost, 2015, 13(1):17-22. doi: 10.1111/jth.12778 pmid: 25381723
[14]	Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time[J]. Blood Adv, 2022, 6(1):307-320.
[15]	Ohashi Y, Ikeda M, Kunitoh H, et al. Corrigendum to: Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry[J]. Jpn J Clin Oncol, 2020, 50(11):1346. doi: 10.1093/jjco/hyaa160 pmid: 32778867
[16]	李甜甜, 石莉程, 孔辉, 等. 肺腺癌并发静脉血栓栓塞症的危险因素及其预测效能[J]. 山东医药, 2021, 61(18):84-87.
[17]	Zhu VW, Zhao JJ, Gao Y, et al. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis[J]. Lung Cancer, 2021, 157:147-155. doi: 10.1016/j.lungcan.2021.05.019 pmid: 34049720
[18]	Al-Samkari H, Leiva O, Dagogo-Jack I, et al. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC[J]. J Thorac Oncol, 2020, 15(9):1497-1506. doi: S1556-0864(20)30380-4 pmid: 32437899
[19]	Ala-Seppälä HM, Ukkonen MT, Laurikka JO, et al. The early and long-term occurrence of symptomatic venous thromboembolism after lung cancer surgery without extended thromboprophylaxis-a single center experience with 435 patients[J]. J Thorac Dis, 2024, 16(7):4329-4339. doi: 10.21037/jtd-24-308 pmid: 39144340
[20]	杜晖, 赵洪林, 赵青春, 等. 肺癌术后患者下肢深静脉血栓的发生率及相关危险因素分析[J]. 中国肺癌杂志, 2023, 26(5):386-391.
[21]	Huang H, Korn JR, Mallick R, et al. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: A retrospective database study[J]. J Thromb Thrombolysis, 2012, 34(4):446-456.
[22]	Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment[J]. Cancers (Basel), 2018, 10(10):380.
[23]	Mitani A, Jo T, Yasunaga H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy[J]. Anticancer Drugs, 2018, 29(6):560-564. doi: 10.1097/CAD.0000000000000625 pmid: 29570101
[24]	Grover SP, Hisada YM, Kasthuri RS, et al. Cancer therapy-associated thrombosis[J]. Arterioscler Thromb Vasc Biol, 2021, 41(4):1291-1305. doi: 10.1161/ATVBAHA.120.314378 pmid: 33567864
[25]	Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the arbeitsgemeinschaft internistische onkologie[J]. J Clin Oncol, 2008, 26(9):1435-1442.
[26]	Chen N, Ren M, Li R, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma[J]. Mol Cancer, 2015, 14:140. doi: 10.1186/s12943-015-0418-x pmid: 26215730
[27]	Lorenzi M, Ferro A, Cecere F, et al. First-line osimertinib in patients with EGFR-Mutant advanced non-small cell lung cancer: Outcome and Safety in the real world: FLOWER study[J]. Oncologist, 2022, 27(2):87-e115.
[28]	Regev A, Avigan MI, Kiazand A, et al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development[J]. J Autoimmun, 2020, 114:102514.
[29]	Alghamdi EA, Aljohani H, Alghamdi W, et al. Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports[J]. Saudi Pharm J, 2022, 30(8):1193-1199. doi: 10.1016/j.jsps.2022.06.010 pmid: 36164566
[30]	Byrne M, Reynolds JV, O'Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery[J]. Br J Cancer, 2010, 102(1):73-79.
[31]	Temraz S, Moukalled N, Gerotziafas GT, et al. Association between radiotherapy and risk of cancer associated venous thromboembolism: A sub-analysis of the COMPASS-CAT study[J]. Cancers (Basel), 2021, 13(5):1033.
[32]	董鲜桃, 张永杰, 朱姝, 等. 肺癌化疗患者经外周静脉穿刺的中心静脉导管置管后发生上肢深静脉血栓的危险因素及其风险预测列线图模型构建[J]. 实用心脑肺血管病杂志, 2022, 30(8):8-12.
[33]	Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy[J]. Blood, 2021, 137(12):1669-1678. doi: 10.1182/blood.2020007878 pmid: 33067632
[34]	Herre M, Cedervall J, Mackman N, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembol neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases[J]. Physiol Rev, 2023, 103(1):277-312.
[35]	LEVIN J, CONLEY CL. THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE[J]. Arch Intern Med, 1964, 114:497-500. pmid: 14184638
[36]	Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis[J]. Hamostaseologie, 2014, 34(1):54-62. doi: 10.5482/HAMO-13-10-0054 pmid: 24305775
[37]	Anghel L, Sascău R, Radu R, et al. From classical laboratory parameters to novel biomarkers for the diagnosis of venous thrombosis[J]. Int J Mol Sci, 2020, 21(6):1920.
[38]	Hisada Y, Garratt KB, Maqsood A, et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer[J]. Blood Adv, 2021, 5(2):487-495. doi: 10.1182/bloodadvances.2020003149 pmid: 33496742
[39]	Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1[J]. Blood, 2010, 116(1):113-121. doi: 10.1182/blood-2010-02-267740 pmid: 20385790
[40]	Gogia S, Neelamegham S. Role of fluid shear stress in regulating VWF structure, function and related blood disorders[J]. Biorheology, 2015, 52(5-6):319-335. doi: 10.3233/BIR-15061 pmid: 26600266
[41]	Hisada Y, Mackman N. Mechanisms of cancer-associated thrombosis[J]. Res Pract Thromb Haemost, 2023, 7(3):100123.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991.
[2]	Huang Ping, Liu Hanyun, Li Yuhong. Risk factors of lung cancer with pulmonary embolism:a meta-analysis [J]. Clinical Focus, 2021, 36(12): 1061-1066.
[3]	. [J]. Clinical Focus, 2021, 36(12): 1132-1135.
[4]	Li Guanzhu, Lai Yuan, Zheng Xiaozhuo, Jiang Ran, Wei Ke. Effects of goal-directed fluid therapy on intraoperative balance between oxygen delivery and consumption and postoperative outcomes in thoracic surgery patients: a meta-analysis [J]. Clinical Focus, 2021, 36(8): 677-684.
[5]	Xu Ying, Han Caijuan, Fan Hong, Meng Zerong, Wang Xiaojun, Liu Hua. Relationship between long non-coding RNA overexpression and poor prognostic of small cell lung cancer: a meta-analysis [J]. Clinical Focus, 2021, 36(8): 685-690.
[6]	Wang Ai. Effects of Kangai injection combined with bevacizumab and DP scheme on efficacy and serum tumor markers and prognosis of NSCLC [J]. Clinical Focus, 2021, 36(6): 517-521.
[7]	Yang Ke, Chen Jun. Value of serum NSE, CEA and CA125 levels in diagnosis and efficacy evaluation of patients with small cell lung cancer [J]. Clinical Focus, 2021, 36(3): 225-228.
[8]	Liu Xinyan,Wei Hongyan, Dai Xianli, Liu Ying. Clinical efficacy of chemotherapy combined with location intervened by bronchoscope in central lung cancer [J]. Clinical Focus, 2016, 31(4): 389-391.
[9]	Li Yajie;Chen Kai. Analysis of transbronchial needle aspiration in 224 cases with mediastinal lymphadenectasis [J]. Clinical Focus, 2015, 30(10): 1159-1162.
[10]	. @@ [J]. Clinical Focus, 2015, 30(10): 1197-1200.
[11]	Chi Hongwei;Wang Canghai;Yang Zhiming;Ren Jinjun;Xu Qian;Chen Yanfang. Appilcation of apparent diffusion coefficient value in chemotherapy efficacy evaluation on non-small cell lung carcinoma [J]. Clinical Focus, 2015, 30(8): 883-887.
[12]	Du Junhua;Yin Yifa;Qiao Hongyuan. Effect of maintenance therapy with Huisheng Oral Liquid for patients in mid-advanced non-small cell lung cancer [J]. Clinical Focus, 2015, 30(6): 641-644.
[13]	Hu Shanshan;Zhang Shun;Cai Ting. Immunochemotherapy for advanced non-small cell lung cancer:a meta-analysis [J]. Clinical Focus, 2015, 30(3): 283-289.
[14]	Li Long;Tang Fabing;Yu Qin. Expression of EGFR and RAS/MAPK signal pathway-related proteins and their significance in lung adenocarcinoma [J]. Clinical Focus, 2015, 30(3): 290-292296.
[15]	Chen Yunping;Li Jiancheng;Zhang Jiangling;Hong Chaoxin;Luo Danfeng;Lai Zhangchao. Clinical effect of intensity modulated radiation therapy for treatment of local medium and advanced non-small cell lung cancer [J]. Clinical Focus, 2015, 30(1): 48-5051.